Literature DB >> 21892678

The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.

Y F Li1, C C Zhou, J H Li, E Luo, S S Zhu, G Feng, J Hu.   

Abstract

UNLABELLED: Ovariectomized (OVX) rats with tibial fracture received vehicle, ZA, PTH, or ZA plus PTH treatment for 4 and 8 weeks. Bone metabolism, callus formation, and the mass of undisturbed bone tissue were evaluated by serum analysis, histology, immunohistochemistry, radiography, micro-computerized tomography, and biomechanical test.
INTRODUCTION: Previous studies have demonstrated the effect of ZA or PTH on osteoporotic fracture healing. However, reports about effects of ZA plus PTH on callus formation of osteoporotic fracture were limited. This study was designed to investigate the impact of combined treatment with ZA and PTH on fracture healing in OVX rats.
METHODS: Twelve weeks after bilateral ovariectomy, all rats underwent unilateral transverse osteotomy on tibiae. Animals then randomly received vehicle, ZA (1.5 μg/kg weekly), PTH (60 μg/kg, three times a week), or ZA plus PTH until death at 4 and 8 weeks. The blood and bilateral tibiae of rats were harvested for evaluation.
RESULTS: All treatments increased callus formation and strength other than the control; ZA + PTH showed the strongest effects on percent bone volume (BV/TV), trabecular thickness, total fluorescence-marked callus area, and biomechanical strength. Additionally, inhibited RANKL and enhanced osteoprotegerin expression were observed in the ZA + PTH group. But no difference in bone mineral density and BV/TV of the contralateral tibiae was observed between treated groups.
CONCLUSION: Findings in this study suggested an additive effect of ZA and PTH on fracture healing in OVX rats, and this additive effect was specific to callus formation, not to undisturbed bone tissue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892678     DOI: 10.1007/s00198-011-1751-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  43 in total

1.  Characteristics of newly formed bone during guided bone regeneration: observations by immunohistochemistry and confocal laser scanning microscopy.

Authors:  K Matsuzaka; M Shimono; T Inoue
Journal:  Bull Tokyo Dent Coll       Date:  2001-11

2.  The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

Authors:  Jawl-Shan Hwang; Lin-Show Chin; Jung-Fu Chen; Tzay-Shing Yang; Po-Quang Chen; Keh-Sung Tsai; Ping Chung Leung
Journal:  J Bone Miner Metab       Date:  2010-10-05       Impact factor: 2.626

3.  Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on cancellous and cortical bone of femoral neck in ovariectomized rats.

Authors:  L Zhang; N Endo; N Yamamoto; T Tanizawa; H E Takahashi
Journal:  Tohoku J Exp Med       Date:  1998-10       Impact factor: 1.848

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Authors:  Dennis M Black; Susan L Greenspan; Kristine E Ensrud; Lisa Palermo; Joan A McGowan; Thomas F Lang; Patrick Garnero; Mary L Bouxsein; John P Bilezikian; Clifford J Rosen
Journal:  N Engl J Med       Date:  2003-09-20       Impact factor: 91.245

6.  Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation.

Authors:  Glenda J Pettway; Jeffrey A Meganck; Amy J Koh; Evan T Keller; Steven A Goldstein; Laurie K McCauley
Journal:  Bone       Date:  2007-12-15       Impact factor: 4.398

7.  Osteogenic response of bone marrow stromal cells from normal and ovariectomized rats treated with a low dose of basic fibroblast growth factor.

Authors:  Mathew Varkey; Cezary Kucharski; Michael R Doschak; Shelley R Winn; Elsa J Brochmann; Samuel Murray; John R Matyas; Ronald F Zernicke; Hasan Uludag
Journal:  Tissue Eng       Date:  2007-04

8.  Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Authors:  Louis C Gerstenfeld; Daniel J Sacks; Megan Pelis; Zachary D Mason; Dana T Graves; Mauricio Barrero; Michael S Ominsky; Paul J Kostenuik; Elise F Morgan; Thomas A Einhorn
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741

9.  The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

Authors:  P D Delmas; P Vergnaud; M E Arlot; P Pastoureau; P J Meunier; M H Nilssen
Journal:  Bone       Date:  1995-06       Impact factor: 4.398

10.  Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.

Authors:  M Li; L Mosekilde; C H Søgaard; J S Thomsen; T J Wronski
Journal:  Bone       Date:  1995-06       Impact factor: 4.398

View more
  24 in total

Review 1.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

2.  Parathyroid hormone (1-34) promotes fracture healing in ovariectomized rats with type 2 diabetes mellitus.

Authors:  G Y Liu; G L Cao; F M Tian; H P Song; L L Yuan; L D Geng; Z Y Zheng; L Zhang
Journal:  Osteoporos Int       Date:  2017-08-14       Impact factor: 4.507

3.  The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.

Authors:  Jian Wu; Xian-Hua Cai; Xing-Xing Qin; Yan-Xi Liu
Journal:  Z Gerontol Geriatr       Date:  2017-03-31       Impact factor: 1.281

4.  Effects of combined human parathyroid hormone (1-34) and menaquinone-4 treatment on the interface of hydroxyapatite-coated titanium implants in the femur of osteoporotic rats.

Authors:  Hang Li; Qiang Zhou; Bing-Li Bai; She-Ji Weng; Zong-Yi Wu; Zhong-Jie Xie; Zhen-Hua Feng; Liang Cheng; Viraj Boodhun; Lei Yang
Journal:  J Bone Miner Metab       Date:  2017-12-26       Impact factor: 2.626

5.  Combined treatment with parathyroid hormone (1-34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model.

Authors:  Zhou-Shan Tao; Kai-Kai Tu; Zheng-Liang Huang; Qiang Zhou; Tao Sun; Hong-Ming Xu; Yu-Long Zhou; Yang-Xun Lv; Wei Cui; Lei Yang
Journal:  Med Biol Eng Comput       Date:  2015-10-01       Impact factor: 2.602

6.  Effect of teriparatide on repair of femoral metaphyseal defect in ovariectomized rats.

Authors:  Zhou-Shan Tao; Yang-Xun Lv; Wei Cui; Zheng-Liang Huang; Kai-Kai Tu; Qiang Zhou; Tao Sun; Lei Yang
Journal:  Z Gerontol Geriatr       Date:  2015-09-10       Impact factor: 1.281

7.  Effectiveness of parathyroid hormone (PTH) analogues on fracture healing: a meta-analysis.

Authors:  K Eastman; M Gerlach; I Piec; J Greeves; W Fraser
Journal:  Osteoporos Int       Date:  2021-02-09       Impact factor: 4.507

8.  Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.

Authors:  Yinghua Zhao; Lei Wang; Yi Liu; Kentaro Akiyama; Chider Chen; Ikiru Atsuta; Tao Zhou; Xiaohong Duan; Yan Jin; Songtao Shi
Journal:  Calcif Tissue Int       Date:  2012-10-12       Impact factor: 4.333

9.  In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.

Authors:  Francesca Salamanna; Melania Maglio; Gianluca Giavaresi; Stefania Pagani; Roberto Giardino; Milena Fini
Journal:  Age (Dordr)       Date:  2015-08-07

10.  Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis.

Authors:  D B Hoffmann; S Sehmisch; A M Hofmann; C Eimer; M Komrakova; D Saul; M Wassmann; K M Stürmer; M Tezval
Journal:  J Bone Miner Metab       Date:  2016-01-29       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.